Stealth reports Phase II extension trial data of elamipretide in mitochondrial myopathy

Stealth BioTherapeutics Inc. (Newton, Mass.) reported data from 30 patients with primary mitochondrial myopathy in the Phase II MMPOWER-2 extension trial showing that once-daily 40 mg subcutaneous elamipretide (MTP-131) missed the primary endpoint

Read the full 333 word article

How to gain access

Continue reading with a
two-week free trial.